Tandem Health
-67%
est. 2Y upside i
Tandem provides a clinician copilot that enables clinicians to focus on providing care, instead of on administrative tasks. Our ambient scribe listens during the patient consultation, transcribes it, and automatically generates a draft medical note that can seamlessly be transferred to your medical record system. Tandem's copilot fully follows GDPR and local patient data laws.
Rank
#1206
Sector
Healthtech, Artificial Intelligence, SaaS
Est. Liquidity
~4Y
Data Quality
Data: HighTandem Health operates in a massive and rapidly growing market for AI medical assistants, with strong customer validation and a robust regulatory moat in Europe.
Last updated: March 10, 2026
Tandem Health successfully expands its AI medical assistant across Europe, leveraging its regulatory compliance (MDR Class IIa, ISO 13485) and deep EHR integrations to capture significant market share from legacy systems and competitors. This drives ARR to over $100M by 2028, justifying a $672M valuation at a premium 6.7x ARR multiple in a rapidly growing market.
Tandem Health maintains strong growth in its core European markets, fending off competition through product differentiation and customer loyalty. ARR reaches $50M by 2028, leading to an acquisition or next funding round at a $345.6M valuation, reflecting a solid 6.9x ARR multiple.
Intense competition from well-funded incumbents and other AI scribe startups, coupled with slower-than-expected market adoption or pricing pressure, limits Tandem Health's growth. The company struggles to raise its next round at a higher valuation, resulting in a down round or a low-multiple acquisition at $48M, significantly impacting common stock value due to liquidation preferences.
Preference Stack Risk
severeFunding Intensity
31%Investors hold $60M in liquidation preferences. In an exit at the current $192M valuation, $132M would be left for common shareholders after preferences are met.
Dilution Risk
highAs a Series A company, multiple future funding rounds are highly probable, which will lead to additional dilution for existing equity holders.
Secondary Liquidity
noneThere is no indication of an active secondary market or tender offers for Tandem Health's equity at this stage.
Questions to Ask at the Interview
Strategic questions based on Tandem Health's data — designed to show you've done your homework.
- 1
“Given the increasing investment by large tech companies like Google and Microsoft in AI for healthcare, how does Tandem Health plan to maintain its competitive edge and defend its market position, particularly in areas where incumbents might have greater resources or existing customer bases?”
- 2
“With $12M ARR and a focus on European expansion, what are the key milestones and growth strategies Tandem Health is targeting to scale its revenue significantly over the next two years, and how will these be achieved amidst a competitive landscape with many alternatives?”
- 3
“Considering the $60M in total funding relative to the $192M valuation, what is the company's strategy for future funding rounds and potential liquidity events, and how does it plan to manage dilution and ensure meaningful returns for common stock holders?”
Community
Valuation Sentiment
Our model estimates -67% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.